{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:11:42Z","timestamp":1785417102663,"version":"3.56.0"},"reference-count":66,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Cystic fibrosis (CF) is a rare genetic disorder commonly affecting multiple organs such as the lungs, pancreas, liver, kidney, and intestine. Our search focuses on the pathophysiological changes that affect the drugs\u2019 absorption, distribution, metabolism, and excretion (ADME). This review aims to identify the ADME data that compares the pharmacokinetics (PK) of different drugs in CF and healthy subjects. The published data highlight multiple factors that affect absorption, such as the bile salt precipitation and the gastrointestinal pH. Changes in CF patients\u2019 protein binding and body composition affected the drug distribution. The paper also discusses the factors affecting metabolism and renal elimination, such as drug\u2013protein binding and metabolizing enzyme capacity. The majority of CF patients are on multidrug therapy, which increases the risk of drug\u2013drug interactions (DDI). This is particularly true for those receiving the newly developed transmembrane conductance regulator (CFTR), as they are at a higher risk for CYP-related DDI. Our research highlights the importance of meticulously evaluating PK variations and DDIs in drug development and the therapeutic management of CF patients.<\/jats:p>","DOI":"10.3390\/medicines12010001","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:00:37Z","timestamp":1735628437000},"page":"1","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Pharmacokinetic Changes in Cystic Fibrosis Patients Population: Narrative Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Ayda","family":"Awaness","sequence":"first","affiliation":[{"name":"Pharmacy School, West Coast University, Los Angeles, CA 90004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Elkeeb","sequence":"additional","affiliation":[{"name":"Pharmacy School, West Coast University, Los Angeles, CA 90004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Afshari","sequence":"additional","affiliation":[{"name":"Pharmacy School, West Coast University, Los Angeles, CA 90004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-7977","authenticated-orcid":false,"given":"Eman","family":"Atef","sequence":"additional","affiliation":[{"name":"Pharmacy School, West Coast University, Los Angeles, CA 90004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_2","first-page":"E11","article-title":"Differences in gene mutations between Chinese and Caucasian cystic fibrosis patients","volume":"52","author":"Zheng","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_4","first-page":"564","article-title":"Cystic Fibrosis: Diagnosis and Treatment","volume":"114","author":"Naehrig","year":"2017","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_5","first-page":"917","article-title":"Analysis of CFTR Gene Mutations in Children with Cystic Fibrosis First Report from North-East of Iran","volume":"16","author":"Mehdizadeh","year":"2013","journal-title":"Iran J Basic Med Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"MBoC"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1126\/science.1712985","article-title":"Effect of deleting the R domain on CFTR-generated chloride channels","volume":"253","author":"Rich","year":"1991","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4081\/mrm.2020.690","article-title":"Novel therapeutic approaches for the management of cystic fibrosis","volume":"15","author":"Jaques","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_10","first-page":"183","article-title":"Intraluminal pH of the human gastrointestinal tract","volume":"46","author":"Fallingborg","year":"1999","journal-title":"Dan. Med. Bull."},{"key":"ref_11","first-page":"513","article-title":"Gastrointestinal pH, Motility\/Transit and Permeability in Cystic Fibrosis","volume":"23","author":"Gregory","year":"1996","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF01296029","article-title":"Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects","volume":"32","author":"Youngberg","year":"1987","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/thx.42.1.59","article-title":"Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis","volume":"42","author":"Stead","year":"1987","journal-title":"Thorax"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/gut.33.5.707","article-title":"Vitamin A absorption in cystic fibrosis: Risk of hypervitaminosis A","volume":"33","author":"James","year":"1992","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/gut.34.8.1137","article-title":"Intestinal bile acid malabsorption in cystic fibrosis","volume":"34","author":"Mulcahy","year":"1993","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jcf.2018.08.009","article-title":"Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis","volume":"18","author":"Bodewes","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/00365528809090233","article-title":"Ileal pH in Cystic fibrosis","volume":"23","author":"Gilbert","year":"1988","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365521.2012.699548","article-title":"Gastrointestinal transit times and motility in patients with cystic fibrosis","volume":"47","author":"Hedsund","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_19","first-page":"66","article-title":"Lactulose-Rhamnose Intestinal Permeability in Children With Cystic Fibrosis","volume":"6","author":"Forget","year":"1987","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.49.12.5013-5017.2005","article-title":"Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis","volume":"49","author":"Beringer","year":"2005","journal-title":"AAC"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bulitta, J.B., Jiao, Y., Landersdorfer, C.B., Sutaria, D.S., Tao, X., Shin, E., H\u00f6hl, R., Holzgrabe, U., Stephan, U., and S\u00f6rgel, F. (2019). Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11070323"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00006454-198712000-00009","article-title":"Drug Disposition in Cystic fibrosis: Progress in understanding pathophysiology and pharmacokinetics","volume":"6","author":"Prandota","year":"1987","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/gut.25.5.500","article-title":"Effect of intrajejunal acidity on aqueous phase bile acid and lipid concentrations in pancreatic steatorrhoea due to cystic fibrosis","volume":"25","author":"Fitzpatrick","year":"1984","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40262-018-0678-x","article-title":"Four Decades of \u03b2-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis","volume":"58","author":"Bulitta","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40262-020-00932-9","article-title":"Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019","volume":"59","author":"Gasthuys","year":"2020","journal-title":"Clin. Pharmacokinet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1172\/JCI105889","article-title":"Retinol-binding protein: The transport protein for vitamin A in human plasma","volume":"47","author":"Kanai","year":"1968","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1128\/AAC.30.2.260","article-title":"Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients","volume":"30","author":"LeBel","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/AAC.31.6.915","article-title":"Pharmacokinetics of ciprofloxacin in cystic fibrosis","volume":"31","author":"Davis","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003088-198815010-00005","article-title":"Arvidsson. Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis","volume":"15","author":"Hedman","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_30","first-page":"1038","article-title":"Enhanced renal excretion of dicloxacillin in patients with Cystic fibrosis","volume":"56","author":"Jusko","year":"1975","journal-title":"Pediatrics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/clpt.1990.83","article-title":"Altered disposition of fleroxacin in patients with cystic fibrosis","volume":"47","author":"Mimeault","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1592\/phco.28.7.883","article-title":"Lack of Effect of P-glycoprotein Inhibition on Renal Clearance of Dicloxacillin in Patients with Cystic Fibrosis","volume":"28","author":"Beringer","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0022-3476(84)80375-3","article-title":"Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study","volume":"105","author":"Levy","year":"1984","journal-title":"J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1991.47","article-title":"Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim","volume":"49","author":"Hutabarat","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2018.07.054","article-title":"First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers","volume":"123","author":"Jiao","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.1991.209","article-title":"Disposition of drugs in cystic fibrosis. III. Acetaminophen","volume":"50","author":"Hutabarat","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","first-page":"434","article-title":"Assessment of Hepatic Function in Cystic Fibrosis by Lidocaine Metabolism","volume":"32","author":"Gremse","year":"2001","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejpb.2016.11.034","article-title":"Food, gastrointestinal pH, and models of oral drug absorption","volume":"112","author":"Abuhelwa","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"a009746","DOI":"10.1101\/cshperspect.a009746","article-title":"The Cystic Fibrosis of Exocrine Pancreas","volume":"3","author":"Wilschanski","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jcf.2021.05.016","article-title":"Review of Gastrointestinal Motility in Cystic Fibrosis","volume":"20","author":"Henen","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01308170","article-title":"Gut hormones and gastrointestinal motility in children with cystic fibrosis","volume":"37","author":"Murphy","year":"1992","journal-title":"Dig. Dis. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Van Der Meer, R., Wilms, E.B., and Heijerman, H.G.M. (2021). CFTR Modulators: Does One Dose Fit All?. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060458"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31949-0","article-title":"Biliary secretion and excretion in health and disease: Current concepts","volume":"6","author":"Hofmann","year":"2007","journal-title":"Ann. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1743-7075-2-11","article-title":"Mechanisms of lipid malabsorption in Cystic Fibrosis: The impact of essential fatty acids deficiency","volume":"2","author":"Peretti","year":"2005","journal-title":"Nutr. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.3748\/wjg.v19.i46.8552","article-title":"Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases","volume":"19","author":"Haack","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ajcn\/64.4.635","article-title":"Vitamin A status in acute exacerbations of cystic fibrosis","volume":"64","author":"Duggan","year":"1996","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcf.2007.07.002","article-title":"Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis","volume":"7","author":"Maqbool","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e220740","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of Body Mass Index With Clinical Outcomes in Patients With Cystic Fibrosis","volume":"5","author":"Nagy","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/AAC.00936-09","article-title":"Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers","volume":"54","author":"Bulitta","year":"2010","journal-title":"AAC"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1023\/A:1015191511817","article-title":"Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?","volume":"19","author":"Susanto","year":"2002","journal-title":"Pharm. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0022-3476(82)80663-X","article-title":"Dosing implications of altered gentamicin disposition in patients with cystic fibrosis","volume":"100","author":"Kearns","year":"1982","journal-title":"J. Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/106002809302700117","article-title":"Hepatic drug metabolism in cystic fibrosis: Recent developments and future directions","volume":"27","author":"Kearns","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199835040-00004","article-title":"Drug Disposition in Cystic Fibrosis","volume":"35","author":"Rey","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mpd.2003.mpd0332","article-title":"Montelukast pharmacokinetics in cystic fibrosis","volume":"142","author":"Graff","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/AAC.36.11.2512","article-title":"Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients","volume":"36","author":"Christensson","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clpt.2003.10.005","article-title":"Activities of Cytochrome P450 1A2, N-acetyltransferase 2, Xanthine oxidase, and Cytochrome P450 2D6 are Unaltered in Children with Cystic Fibrosis","volume":"75","author":"Kennedy","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/arrd.1983.127.4.417","article-title":"Theophylline disposition in cystic fibrosis","volume":"127","author":"Isles","year":"1983","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2004.10.007","article-title":"Cytochrome P450-mediated metabolism of estrogens and its regulation in human","volume":"227","author":"Tsuchiya","year":"2005","journal-title":"Cancer Lett."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Murphy, J.E., FASHP, and FCCP (2022). Clinical Pharmacokinetics, ASHP. [7th ed.].","DOI":"10.37573\/9781585286607"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/cpt.2585","article-title":"Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19","volume":"111","author":"Hong","year":"2022","journal-title":"Clin Pharma Ther."},{"key":"ref_61","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta\u00ae\/Kaftrio","volume":"22","author":"Purkayastha","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_64","unstructured":"Brody, T. (2018). FDA\u2019s drug review process and the package label. ScienceDirect, Academic Press."},{"key":"ref_65","first-page":"54","article-title":"Pharmacogenomics of Cystic Fibrosis","volume":"1","author":"Pollard","year":"2001","journal-title":"Mol. Interv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/12\/1\/1\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:52Z","timestamp":1760115472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/12\/1\/1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["medicines12010001"],"URL":"https:\/\/doi.org\/10.3390\/medicines12010001","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}